Methods for treating pustular conditions of the skin

a technology for pustular conditions and skin, applied in the direction of biocide, drug composition, therapy, etc., to achieve the effect of accelerating skin pustular conditions, reducing bioburden, and accelerating wound healing

Inactive Publication Date: 2009-01-01
STEMNION
View PDF2 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013]The compositions described herein have previously been shown to be useful in treating wounds (details are contained in US Publication No. 2006-0222634-A1 and US Publication No. 2007-0231297 A1, which are incorporated herein by reference). In particular, the compositions described herein have been demonstrated to accelerate wound healing in chronic, infected wounds, even though the compositions themselves are not able to reduce bioburden in such infected wounds. Therefore, the compositions described herein may accelerate healing of pustular conditions of the skin faster and with less scarring than other available treatments, and such accelerated healing may be further enhanced when used in combination with antibiotic treatment or other treatment mo

Problems solved by technology

In particular, the compositions described herein have been demonstrated to accelerate wound healing in chronic, i

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of AMP Cell Compositions

[0098]Recovery of AMP cells—AMP cells were dissociated from starting amniotic membrane using the dissociation agents PXXIII, and trypsin. The average weight range of an amnion was 18-27 g. The number of cells recovered per g of amnion was about 10-15×106 for dissociation with PXXIII and 5-8×106 for dissociation with trypsin.

[0099]Method of obtaining selected AMP cells: Cells were plated immediately upon isolation from the amnion. After 2 days in culture non-adherent cells were removed and the adherent cells were kept. This attachment to a plastic tissue culture vessel is the selection method used to obtain the desired population of cells. Adherent and non-adherent AMP cells appear to have a similar cell surface marker expression profile but the adherent cells have greater viability and are the desired population of cells. Adherent AMP cells were cultured until they reached ˜120,000-150,000 cells / cm2. At this point, the cultures were confluent. Sui...

example 2

Generation of ACCS

[0100]The AMP cells of the invention can be used to generate ACCS. The AMP cells were isolated as described herein and 1×106 cells / mL were seeded into T75 flasks containing ˜10 mL culture medium. The cells were cultured until confluent, the medium was changed and ACCS was collected 3 days post-confluence. Skilled artisans will recognize that other embodiments for collecting ACCS from confluent cultures, such as using other tissue culture vessels, including but not limited to cell factories, flasks, hollow fibers, or suspension culture apparatus, are also contemplated by the methods of the invention. It is also contemplated by the instant invention that the ACCS be cryopreserved, lyophilized or formulated, for example, into sustained-release formulations following collection.

example 3

Generation of Pooled ACCS

[0101]ACCS was obtained essentially as described above. In certain embodiments, ACCS was collected multiple times from an AMP culture derived from one placenta and these multiple ACCS collections were pooled together. Such pools are referred to as “SP pools” (more than one ACCS collection / one placenta). In another embodiment, AMP cultures were derived from several placentas, i.e. from 5 or 10 placentas. The AMP cells from each placenta were cultured and one ACCS collection from each culture was collected and then they were all pooled. These pools are termed “MP1 pools” (one ACCS collection / placenta, multiple placentas). In yet another embodiment, AMP cell cultures were derived from several placentas, i.e. from 5 or 10 placentas. The AMP cells from each placenta were cultured and more than one ACCS collection was performed from each AMP cell culture and then pooled. These pools are termed “MP2 pools” (more than one ACCS collection / placenta, multiple placentas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention is directed to methods for treating pustular conditions of the skin, for example, acne. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority under 35 USC §119(e) of U.S. Provisional Application No. 60 / 937,231, filed Jun. 26, 2007, the entirety of which is incorporated herein by reference.FIELD OF THE INVENTION[0002]The field of the invention is directed to methods for treating pustular conditions of the skin. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.BACKGROUND OF THE INVENTION[0003]Generalized pustular conditions of the skin include pustular psoriasis, Reiter's disease and subcorneal pustular dermatosis. Medications can cause gen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/12A61P17/10A61K35/48
CPCA61K35/48A61K8/982A61K31/56A61K31/573A61K45/06A61N5/0616A61K35/50A61P17/10
Inventor PALLADINO, LINDA O.MARSHALL, VIVIENNE S.CLARKE, DIANA L.SMITH, CHARLOTTE A.ROBSON, MARTIN C.
Owner STEMNION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap